Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li, Aaron A. Bickert, Adrian Perdyan, Shreyasee V. Kumbhar, Sujan Piya, Amari M. Sockwell, Sami J. Morse, Kent A. Arian, Hikaru Sugimoto, Shabnam Shalapour, David S. Hong, Timothy Paul Heffernan, Anirban Maitra, Raghu Kalluri
This study identifies small molecule Kras inhibitors that synergize with anti-CTLA4 therapy to reprogram Tregs and enhance immunotherapy efficacy in PDAC.
bioRxiv · Feb 28, 2025 · PreprintCancer Biology